- Home
- CELC vs VNET Comparison
CELC vs VNET Comparison
Compare CELC & VNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- VNET
- Stock Information
- Founded
- CELC 2011
- VNET 1999
- Country
- CELC United States
- VNET China
- Employees
- CELC N/A
- VNET N/A
- Industry
- CELC Medical Specialities
- VNET Computer Software: Programming Data Processing
- Sector
- CELC Health Care
- VNET Technology
- Exchange
- CELC Nasdaq
- VNET Nasdaq
- Market Cap
- CELC 594.7M
- VNET 531.1M
- IPO Year
- CELC 2017
- VNET 2011
- Fundamental
- Price
- CELC $12.66
- VNET $3.45
- Analyst Decision
- CELC Strong Buy
- VNET Strong Buy
- Analyst Count
- CELC 6
- VNET 3
- Target Price
- CELC $29.17
- VNET $4.60
- AVG Volume (30 Days)
- CELC 257.7K
- VNET 1.5M
- Earning Date
- CELC 11-14-2024
- VNET 11-20-2024
- Dividend Yield
- CELC N/A
- VNET N/A
- EPS Growth
- CELC N/A
- VNET N/A
- EPS
- CELC N/A
- VNET N/A
- Revenue
- CELC N/A
- VNET $1,056,473,872.00
- Revenue This Year
- CELC N/A
- VNET $9.88
- Revenue Next Year
- CELC N/A
- VNET $12.11
- P/E Ratio
- CELC N/A
- VNET N/A
- Revenue Growth
- CELC N/A
- VNET 4.85
- 52 Week Low
- CELC $11.51
- VNET $1.39
- 52 Week High
- CELC $22.19
- VNET $4.50
- Technical
- Relative Strength Index (RSI)
- CELC 28.22
- VNET 49.01
- Support Level
- CELC $15.33
- VNET $3.37
- Resistance Level
- CELC $16.14
- VNET $3.58
- Average True Range (ATR)
- CELC 0.97
- VNET 0.22
- MACD
- CELC -0.28
- VNET -0.01
- Stochastic Oscillator
- CELC 22.85
- VNET 33.33
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About VNET VNET Group Inc.
VNET started as AsiaCloud in 1999 and moved to the data center business with its first self-developed data center opening in 2010. The firm listed (as 21Vianet) on the Nasdaq in April 2011, subsequently changing its name to VNET Group in 2021. It originally focused on providing data center services such as colocation and cloud services to retail clients in China, but added hyperscale customers in 2019 and now counts large Chinese hyperscalers such as Alibaba Cloud, Tencent Cloud, and Huawei Cloud as customers. At the end of March 2024, it had 48,503 self-built retail cabinets with the majority in Beijing, Shanghai, and the Greater Bay area. It also had 332 MW of wholesale capacity in service with a further 139 MW under construction and a further 557 MW held for future development.